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Abstract
Objective: This study examined the time course of efficacy-related endpoints for lisdexamfetamine dimesylate (LDX) versus placebo in adults with protocol-defined moderate to severe binge-
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eating disorder (BED).
Methods: In two 12-week, double-blind, placebo-controlled studies, adults meeting DSM-IV-TR
BED criteria were randomized 1:1 to receive placebo or dose-optimized LDX (50 or 70 mg).
Analyses across visits used mixed-effects models for repeated measures (binge eating days/week,
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binge eating episodes/week, Yale-Brown Obsessive Compulsive Scale modified for Binge
Eating [Y-BOCS-BE] scores, percentage body weight change) and chi-square tests (Clinical Global
Impressions—Improvement [CGI-I; from the perspective of BED symptoms] scale dichotomized as
improved or not improved). These analyses were not part of the prespecified testing strategy, so
reported p values are nominal (unadjusted and descriptive only).
Results: Least squares mean treatment differences for change from baseline in both studies
favored LDX over placebo (all nominal p values < .001) starting at Week 1 for binge eating
days/week, binge-eating episodes/week, and percentage weight change and at the first posttreatment assessment (Week 4) for Y-BOCS-BE total and domain scores. On the CGI-I, more
participants on LDX than placebo were categorized as improved starting at Week 1 in both
studies (both nominal p values < .001). Across these efficacy-related endpoints, the superiority
of LDX over placebo was maintained at each posttreatment assessment in both studies (all
nominal p values < .001).
Discussion: In adults with BED, LDX treatment appeared to be associated with improvement on
efficacy measures as early as 1 week, which was maintained throughout the 12-week studies.
KEYWORDS

binge-eating disorder, efficacy, lisdexamfetamine, time course
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1 | INTRODUCTION
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of the Declaration of Helsinki. Participants provided written informed
consent before entering the studies.

Lisdexamfetamine dimesylate (LDX) is approved for use in adults with

Each study included a 2-week screening phase, a 12-week double-

moderate to severe binge-eating disorder (BED) in the United States

blind phase (4 weeks of dose optimization followed by 8 weeks of dose

(Vyvanse®, 2015). In two large, identically designed, 12-week,

maintenance), and a follow-up visit. After screening, participants were

dose-optimized, randomized, double-blind, placebo-controlled, Phase 3

randomized 1:1 to receive 12 weeks of dose-optimized LDX or matching

studies in adults with protocol-defined moderate to severe BED,

placebo. For blinding, both treatments were identical in appearance. Treat-

dose-optimized LDX (50 or 70 mg/day) produced statistically superior

ment was initiated with 30 mg LDX during Week 1 and titrated to 50 mg

and clinically meaningful reductions in binge eating days/week at

LDX at the start of Week 2. During Week 3, dose increases to 70 mg LDX

weeks 11–12 (primary efficacy endpoint) versus placebo (McElroy

could be made based on tolerability and clinical need. After the LDX dose

et al., 2015a). In these Phase 3 trials, statistically significant and clini-

was increased to 70 mg, a single down-titration to 50 mg was allowed dur-

cally meaningful improvements on secondary efficacy endpoints were

ing Week 3 if tolerability to 70 mg LDX was poor. If a dose reduction

also observed for LDX versus placebo at Week 12/early termination

occurred, no further changes were allowed. During Weeks 4 to 12, the

(ET) for including Clinical Global Impressions—Improvement (CGI-I) and

optimized LDX dosage (50 or 70 mg) was maintained. Because no dose

4-week binge eating cessation and at Week 12 for Yale-Brown

changes were permitted beyond Week 3, participants requiring a dose

Obsessive Compulsive Scale modified for Binge Eating (Y-BOCS-BE)

reduction during the maintenance phase were discontinued. A follow-up

and percentage change in body weight (McElroy et al., 2015a). In a

visit occurred 1 week after the final treatment visit (Week 12 or ET) to

Phase 2, fixed-dose, randomized, double-blind, placebo-controlled trial,

assess any ongoing or new safety and tolerability issues.

LDX (50 and 70 mg but not 30 mg) was also superior to placebo in
decreasing binge eating days/week in adults with BED at Week 11
(McElroy et al., 2015b). In these short-term studies (McElroy et al.,
2015a,b), the safety and tolerability of LDX were generally similar to its
established profile for LDX treatment of attention-deficit/hyperactivity
disorder (ADHD) (Vyvanse®, 2015).
Although the main findings for the primary and key secondary efficacy endpoints from the Phase 3 studies of LDX have been published
(McElroy et al., 2015a), these analyses only examined change from
baseline to end of study (Week 12 or Week 12/ET). Statistical assessment of the time course of effects of LDX on efficacy-related endpoints from these studies has not yet been reported. Such data are
important because they provide an indication of how soon treatment
effects may be anticipated after the therapy is initiated. The current
report describes the time course of effects of LDX on efficacy-related
endpoints (binge eating days/week, binge eating episodes/week,
percentage of participants exhibiting improvement on the dichotomized CGI-I, percentage of participants exhibiting 1-week binge eating
response, percentage change in body weight, and Y-BOCS-BE total

2.2 | Participants
Participant inclusion and exclusion criteria have been reported previously (McElroy et al., 2015a). Eligible adults (aged 18–55 years) met the
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text
Revision (DSM-IV-TR) criteria for BED and had protocol-defined
moderate to severe BED (defined as having 3 binge eating days/week
for 14 days before baseline and Clinical Global Impressions—Severity
scores [from the perspective of binge eating symptoms] at screening
and baseline of 4). Key exclusion criteria included current anorexia
nervosa or bulimia nervosa; comorbid current psychiatric disorders
either controlled with prohibited medications or uncontrolled and associated with significant symptoms or any condition that could confound
study assessments; lifetime history of psychosis, mania, hypomania,
dementia, or ADHD; a Montgomery–Åsberg Depression Rating Scale
total score 18 at screening; psychotherapy or weight loss support for
BED within 3 months of screening; being considered a suicide risk in the
opinion of the investigator, having a previous suicide attempt, or currently demonstrating active suicidal ideation; history of cardiovascular

and subscale score changes) in the two previously described 12-week

disorders or moderate or severe hypertension; and lifetime history of

treatment Phase 3 clinical studies (McElroy et al., 2015a).

stimulant abuse, recent history of substance abuse or dependence, or
known or suspected intolerance or hypersensitivity to LDX or related

2 | METHOD

compounds.

2.1 | Study design and treatment

2.3 | Endpoint measures

Detailed descriptions of study designs and participants have been

Binge eating days/week, binge eating episodes/week, and 1-week

reported (McElroy et al., 2015a). In brief, two randomized, placebo-

binge eating response (percentage reductions in binge eating episodes/

controlled, parallel-group, multicenter studies (ClinicalTrials.gov identifier:

week) data were based on participants’ daily self-reported binge eating

NCT01718483 [referred to hereafter as Study 1] and ClinicalTrials.gov

diaries as assessed and confirmed by experienced and trained clinicians.

identifier: NCT01718509 [referred to hereafter as Study 2]) were

Binge eating diaries were assessed at all study visits except screening.

conducted. Study protocols were approved by ethics committees,

The percentage of participants exhibiting 1-week binge eating

and both studies were conducted in accordance with International

responses (reductions in binge-eating episodes/week of 100%,

Conference on Harmonisation Good Clinical Practice and the principles

99–75%, 74–50%, and <50%) was derived at each treatment visit.
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F I G U R E 1 Changes in the frequency of binge eating over time, full analysis set. Mean 6 SD binge eating days/week (A: Study 1; B: Study
2) and mean 6 SD binge-eating episodes/week (C: Study 1; D: Study 2). Abbreviations: LDX5lisdexamfetamine; Pbo5placebo

The CGI-I (Guy, 1976) measured changes in clinical severity

percentage body weight change from baseline at Week 12, and Y-

relative to baseline (score range: 1 [very much improved] to 7 [very

BOCS-BE total score change from baseline at Week 12) have previ-

much worse]). The CGI-I was assessed from the perspective of BED

ously been reported (McElroy et al., 2015a). Time course assessments

symptoms and administered at each postbaseline visit. CGI-I scores

of efficacy-related endpoints are described in this report.

were dichotomized as improved (very much improved and much

Statistical assessments were conducted in the full analysis set (par-

improved; scores of 1 or 2) or not improved (minimally improved to

ticipants taking 1 study drug dose and having 1 postbaseline primary

very much worse; scores of 3–7).

efficacy assessment). The time course analyses presented in the current

The Y-BOCS-BE, a 10-item, clinician-rated scale (item scores: 0

report are analyzed with the same procedures previously described for

[no symptoms] to 4 [extreme symptoms]), assessed the obsessiveness

the prespecified endpoints (McElroy et al., 2015a). Mixed-effects mod-

of binge eating thoughts and compulsiveness of binge eating behaviors.

els for repeated measures analysis over all postbaseline visits, using an

Total scores range from 0 to 40. The Y-BOCS-BE, which is a modified

unstructured covariance matrix with treatment, visit, and the treatment

version of the Yale-Brown Obsessive Compulsive Scale (Goodman

3 visit interaction included as factors and baseline score as a covariate

et al., 1989), has been validated in adults with BED (Deal et al., 2015).

and its interaction with visit also included in the model, were used to

The Y-BOCS-BE was administered at baseline and Weeks 4, 8, and 12.

determine least squares (LS) mean treatment differences (LDX—placebo)

Body weight was measured at each visit, and the percentage change

in the change from baseline for binge eating days/week, binge-eating

from baseline was calculated for each treatment week.

episodes/week, percentage body weight change, and Y-BOCS-BE total
and domain scores; effects size (ES) size was determined based on the

2.4 | Data presentation and statistical analyses

estimated standard deviation from the unstructured covariance matrix.

Statistically significant findings for the prespecified primary efficacy

Degrees of freedom were calculated using the Kenward-Roger approxi-

endpoint (change from baseline in binge eating days/week at Weeks

mation method. Treatment comparisons between LDX and placebo in

11–12) and key secondary endpoints (improvement on the dichotom-

the percentage of participants categorized as improved on the dicho-

ized CGI-I at Week 12/ET, 4-week binge cessation at Week 12/ET,

tomized CGI-I were analyzed using v2 tests; odds ratios (ORs) were
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3 | RESULTS
3.1 | Participant disposition and demographics
Participant disposition has previously been reported (McElroy et al.,
2015a). In brief, most randomized participants completed each study. A
total of 68 participants did not complete Study 1 and 96 participants
did not complete Study 2. Relatively few participants discontinued
because of adverse events or lack of efficacy. The full analysis set
included 374 participants in Study 1 and 350 participants in Study 2.
In Study 1 and Study 2, respectively, most participants in the full
analysis set were white (77.8% [291/374] and 74.0% [259/350]), were
women (86.9% [325/374] and 86.3% [302/350]), and met criteria for
obesity (BMI  30.0 but <35 kg/m2: 25.4% [95/374] and 27.7%
[97/350]; BMI  35.0 but <40 kg/m2: 24.1% [90/374] and 22.3%
[78/350]; BMI  40.0 kg/m2: 17.6% [66/374] and 19.7% [69/350]).
Mean 6 SD age and BMI, respectively, were 38.0 6 10.32 years
and 33.43 6 6.245 kg/m2 in Study 1 and 38.0 6 10.04 years and
33.61 6 6.272 kg/m2 in Study 2.

3.2 | Efficacy analyses
3.2.1 | Binge eating days/week and binge-eating
episodes/week
Improvement on the CGI-I over time, full analysis set.
Percentage (95% CI) of participants categorized as improveda on
the CGI-I (A: Study 1; B: Study 2). aParticipants were categorized
as improved on the CGI-I if a score of 1 (very much improved) or 2
(much improved) was reported. bNominal p < .001; cp < .001
(prespecified key secondary endpoint included in the hierarchical
testing strategy, data previously published [McElroy et al, 2015a]).
d
One participant in the placebo group in Study 2 did not have a
valid Week 12/early termination assessment. Abbreviations: CGII 5 Binge Eating Clinical Global Impressions–Improvement;
ET5early termination; LDX5lisdexamfetamine; Pbo5placebo
FIGURE 2

The baseline mean 6 SD numbers of binge eating days/week and
binge-eating episodes/week, respectively, were 4.60 6 1.210 and
5.96 6 2.551 with placebo and 4.79 6 1.271 and 6.42 6 2.962 with
LDX in Study 1 and 4.82 6 1.422 and 6.62 6 3.797 with placebo and
4.66 6 1.273 and 6.40 6 3.463 with LDX in Study 2. The mean 6 SD
numbers of binge eating days/week (Figure 1A,B) and binge eating episodes/week (Figure 1C,D) decreased with placebo and LDX from
Week 1 through Weeks 11–12 in both studies. For binge eating days/
week, LS mean (95% CI) treatment differences favored LDX from
Week 1 through Weeks 9–10 (all nominal p values < .001; all ES  .57)

calculated as LDX/placebo. For 1-week binge eating response (percent-

and at Weeks 11–12 (both p values < .001; both ES  .83) in both

age reductions in binge eating episodes/week), differences in the distri-

studies (Supporting Information Table 1). For binge eating episodes/

bution of responses between LDX and placebo were compared using a

week, LS mean (95% CI) treatment differences also favored LDX over

covariate-adjusted Cochran–Mantel–Haenszel method, with baseline

placebo from Week 1 through Weeks 11–12 (all nominal p val-

binge eating episodes/week included as the covariate. Cramer’s V was

ues < .001; all ES  .60; Supporting Information Table 1).

calculated using a 2 3 4 contingency table at each visit to assess the
association between the treatment group and binge eating response;
values range from 0 (no association) to 1 (complete association).
Consistent with International Conference on Harmonisation
statistical guidelines (European Medicines Agency, 1998), the control
of multiplicity in each study was prespecified in the statistical analysis
plan; these procedures have previously been described (McElroy et al.,
2015a). The current post hoc time course analyses were not adjusted
for multiple comparisons. As such, the p values reported for these post
hoc time course analyses are nominal (unadjusted for multiplicity and

3.2.2 | Improvement on the CGI-I
The percentage of participants categorized as improved on the CGI-I
increased over the course of both studies with placebo and LDX
(Figure 2A,B). In both studies, the percentage of participants
categorized as improved was greater with LDX than placebo
from Week 1 through Week 12 (all v2 statistics  12.48; degrees of
freedom 5 1; all nominal p values < .001; all ORs  2.32) and at
Week 12/ET (both v2 statistics  49.81; degrees of freedom 5 1; both
p values < .001; both ORs  5.12).

descriptive). In the results, descriptions of the post hoc time course

3.2.3 | 1-Week binge eating response (percentage reductions in

analyses and of the prespecified analyses included in the hierarchical

binge-eating episodes/week) The 1-week binge eating response

testing strategy are presented separately to more clearly differentiate

distributions differed between LDX and placebo in both studies

these analyses.

from Week 1 through Week 12 (all v2 statistics  16.66 based on
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1-week binge eating responses (reductions in binge-eating episodes/week) over time, full analysis set. Percentages of
participants exhibiting reductions in binge eating episodes/week over the prior 7 days (A: Study 1; B: Study 2). aNominal p < .001 for
distribution of binge eating responses. Abbreviations: ET 5 early termination; LDX 5 lisdexamfetamine

FIGURE 3

Cochran–Mantel–Haenszel tests; degrees of freedom 5 1; all nominal

p values < .001; all ES  .56) and at Week 12 (both p values < .001;

p values < .001; all Cramer’s Vs  .28) and at Week 12/ET (both v2

both ES  1.22) (Supporting Information Table 2).

statistics  43.82 based on Cochran–Mantel–Haenszel tests; degrees of
freedom 5 1; both nominal p values < .001; both Cramer’s Vs  .40). The

3.2.5 | Y-BOCS-BE total and domain scores

percentages of participants exhibiting binge eating episode reductions of

Mean 6 SD Y-BOCS-BE total scores (Figure 5A,B) and domain scores

100% and 99% to 75% in the last 7 days were numerically greater with

(Figure 5C–F) decreased (i.e., improved) from baseline with placebo and

LDX than placebo from Week 1 to Week 12 in both studies (Figure 3A,B).

LDX during both studies at each of the three postbaseline assessment
time points. For Y-BOCS-BE total score changes from baseline (Support-

3.2.4 | Body weight

ing Information Table 2), LS mean (95% CI) treatment differences

Mean 6 SD body weight decreased with LDX but not placebo over the

favored LDX at Week 4 and Week 8 (all nominal p values < .001; all

course of both studies (Figure 4A,B), resulting in larger mean 6 SD

ES  .87) and at Week 12 (both p values < .001; both ES  1.03) in both

percentage decreases in body weight from baseline with LDX than pla-

studies. For the binge-related obsessions and binge-related compulsions

cebo (Figure 4C,D). In both studies, the LS mean (95% CI) treatment

domain scores, LS mean (95% CI) treatment differences also favored

differences for the percentage body weight change from baseline

LDX over placebo at Weeks 4, 8, and 12 (all nominal p values < .001; all

favored LDX over placebo from Week 1 through Week 10 (all nominal

ES  .78; Supporting Information Table 2) in both studies.
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F I G U R E 4 Reductions in body weight over time, full analysis set. Mean 6 SD body weight in kg (A: Study 1; B: Study 2) and mean 6 SD
percentage changes in body weight from baseline (C: Study 1; D: Study 2). Abbreviations: ET 5 early termination; LDX 5 lisdexamfetamine;
Pbo5placebo

4 | DISCUSSION

of BED (Vyvanse®, 2015), it was not studied as a target treatment
dose based largely on the Phase 3 pivotal studies in which 30 mg LDX

The key findings of this report are that the treatment effects of LDX

was used only as an initial titration dose and not studied as a target

versus placebo were observed as early as the first week of treatment

dose (McElroy et al., 2015a). Additional research with a study design

across multiple endpoints (binge eating days/week, binge eating epi-

focused on this research question would be needed to draw firmer

sodes/week, 1-week binge eating response, dichotomized improve-

conclusions.

ment on the CGI-I, and percentage change in body weight from

Although medications other than LDX have been investigated

baseline) and at Week 4 on Y-BOCS-BE total and domain scores (the

for potential use as BED pharmacotherapy in double-blind, placebo-

first time point assessed). Furthermore, improvements were maintained

controlled trials, LDX is the only medication currently approved in

for the duration of the 12-week studies. These results support the rela-

the United States for the treatment of adults with moderate to

tively rapid efficacy of LDX in reducing both binge eating behavior and

severe BED (Vyvanse®, 2015). To our knowledge, this is the first

binge eating-related psychopathology in two studies (McElroy et al.,

publication describing time course analyses of treatment effects by

2015a) in which 12 weeks of dose-optimized LDX was shown to pro-

week for the efficacy of a pharmacotherapy in individuals with BED.

duce significantly greater improvement than placebo at the end of the

Based on available data from short-term studies for other potential

study on several of these same measures. Consistent with the results

BED therapies, numerically greater reductions in binge eating

of the Phase 2 study (McElroy et al., 2015b), this post hoc analysis

frequency and body weight for active treatment versus placebo are

revealed a possible treatment effect at Week 1, when 30 mg LDX was

generally observed within 1–4 weeks of starting treatment

being taken by study participants. This finding is difficult to explain

(Appolinario et al., 2003; Guerdjikova et al., 2012; Hudson et al.,

because 30 mg LDX was not statistically superior to placebo in reduc-

1998; McElroy et al., 2000, 2003, 2007; Wilfley et al., 2008). In one

ing log-transformed binge eating days/week at the Week 11 (the pri-

study that reported statistical analysis of treatment effects prior to

mary endpoint) in the Phase 2 study (McElroy et al., 2015b). Although

the end of the study, significantly greater reductions in binge eating

30 mg LDX is a recommended starting titration dose for the treatment

days/week and weight for sibutramine versus placebo were
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Y-BOCS-BE total and domain scores over time, full analysis set. Mean 6 SD Y-BOCS-BE total scores (A: Study 1; B: Study 2),
mean 6 SD Y-BOCS-BE binge-related obsessions domain scores (C: Study 1; D: Study 2), and mean 6 SD binge-related compulsions domain
scores (E: Study 1; F: Study 2). Abbreviations: LDX5lisdexamfetamine; Pbo5placebo; Y-BOCS-BE5Yale-Brown Obsessive Compulsive Scale
modified for Binge Eating
FIGURE 5

reported at treatment Weeks 2 and 4, respectively (Appolinario

associated with significant symptoms were also excluded, as were

et al., 2003).

those with histories of psychosis, mania/hypomania, and ADHD (those

The study has several limitations. These time course analyses were

with mild mood or anxiety symptoms that did not meet diagnostic cri-

not prespecified, were not included in the hierarchical testing strategy,

teria or require treatment could be included), which may limit the gen-

and did not account for multiple comparisons. Therefore, all findings

eralizability of the current findings to a more heterogeneous clinical

related to the time course of effects of LDX are nominal (unadjusted

population. Lastly, it has been reported that in a majority of individuals

for multiplicity and descriptive in nature). In addition, study participants

with bulimia nervosa (combined data from two studies; n 5 785) even-

were mainly women, mainly white, and predominantly met criteria for

tual nonresponse to fluoxetine at the end of 7–8 weeks of fluoxetine

obesity. Study participants with current comorbid psychiatric disorders

treatment is unlikely if reductions in binge eating or vomiting of at least

that were controlled with prohibited medications or uncontrolled and

60% are not observed after 3 weeks of fluoxetine treatment (Sysko,
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Sha, Wang, Duan, & Walsh, 2010). It would also be of interest to assess

R EF ER E N CE S

the relationship between early treatment response to LDX and long-

Appolinario, J. C., Bacaltchuk, J., Sichieri, R., Claudino, A. M., GodoyMatos, A., Morgan, C., . . . Coutinho, W. (2003). A randomized,
double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Archives of General Psychiatry, 60,
1109–1116.

term outcomes in individuals with BED. However, these analyses were
not conducted so the degree to which short-term response to LDX
predicts long-term outcomes cannot be determined.
In conclusion, LDX appeared to be associated with improvement
in efficacy-related endpoints in adults with protocol-defined moderate
to severe BED after 1 week of treatment (after Week 4 [the first
assessment] for the Y-BOCS-BE) and these improvements were maintained for the course of the 12-week treatment period. These results
suggest that LDX reduces both binge eating behavior and binge eatingrelated psychopathology soon after treatment is initiated.
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